Cellectis (CLLS) EBIT Margin (2015 - 2026)
Cellectis (CLLS) recorded quarterly EBIT Margin of 435.64% in Q1 2026, down 219.25% quarter-over-quarter from 136.46% in Q4 2025, and down 30257.0% on a YoY basis from N/an in Q1 2025.
Cellectis (CLLS) EBIT Margin (2015 - 2026) Analysis & Trends
Cellectis' EBIT Margin history runs 12 years deep, the most recent figure standing at 435.64% for Q1 2026.
- In Q1 2026, EBIT Margin fell 30257.0% year-over-year to 435.64%; the TTM figure through Mar 2026 stood at 62.6% (up 3287.0% YoY), while the FY2025 annual figure was 81.64%, up 3937.0% from the prior year.
- EBIT Margin was 435.64% for Q1 2026 at Cellectis, down from 136.46% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 22.86% in Q3 2025 to a low of 16856.83% in Q1 2023.
- Historically, EBIT Margin has averaged 4409.37% across 5 years, with a median of 435.64% in 2026.
- The sharpest annual moves came in 2022 and 2024: EBIT Margin slumped 1512056 bps in 2022, then soared 1639539 bps in 2024.
- A 5-year view of EBIT Margin shows it stood at 35.32% in 2022, then plunged by 29490 bps to 10451.94% in 2023, then soared by 99 bps to 52.28% in 2024, then slumped by 161 bps to 136.46% in 2025, then plunged by 219 bps to 435.64% in 2026.
- The last three EBIT Margin figures came in at 435.64% (Q1 2026), 136.46% (Q4 2025), and 22.86% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | -435.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -435.64% |
| Dec 31, 2025 | -136.46% |
| Sep 30, 2025 | 22.86% |
| Jun 30, 2025 | -57.32% |
| Mar 31, 2025 | -133.07% |
| Dec 31, 2024 | -52.28% |
| Sep 30, 2024 | -66.48% |
| Jun 30, 2024 | -213.51% |
| Mar 31, 2024 | -461.44% |
| Dec 31, 2023 | -10,451.94% |
| Sep 30, 2023 | -13,336.13% |
| Jun 30, 2023 | -13,270.22% |
| Mar 31, 2023 | -16,856.83% |
| Dec 31, 2022 | -35.32% |
| Sep 30, 2022 | -15,630.29% |
| Jun 30, 2022 | -2,089.75% |
| Mar 31, 2022 | -1,755.44% |
| Dec 31, 2021 | -239.33% |
| Sep 30, 2021 | -509.72% |
| Jun 30, 2021 | -335.37% |